5-乙氧基-2-氨基嘧啶 | 39268-74-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-乙氧基-2-氨基嘧啶
• 中文别名: 2-氨基-5-乙氧基嘧啶
• 英文名称: 2-amino-5-ethoxypyrimidine
• 英文别名: 5-ethoxy-pyrimidin-2-ylamine；5-ethoxy-2-pyrimidinamine；2-Amino-5-aethoxy-pyrimidin；2-Amino-5-ethoxy-pyrimidin；5-Ethoxypyrimidin-2-amine
• CAS: 39268-74-1
• 化学式: C₆H₉N₃O
• mdl: MFCD00223638
• 分子量: 139.157
• InChiKey: NGWGYIGTWBAKAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  应存放在室温、避光且处于惰性气体环境中的地方。

反应信息

• 作为反应物：
  描述：

  5-乙氧基-2-氨基嘧啶 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 吡啶 、 硫酸 、 三乙胺 、 lithium chloride 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 28.25h， 生成 4'-{[4-butyl-1-(5-ethoxypyrimidin-2-yl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl]methyl}biphenyl-2-carbonitrile
  参考文献：
  名称：

  NOVEL 2-PYRIDONE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME

  摘要：

  揭示了一种由通式（1）表示的新型2-吡啶酮衍生物，该衍生物具有抗血管紧张素II受体拮抗活性和PPAR-γ激活活性，并且可用作心血管疾病和代谢性疾病的预防和/或治疗剂。还揭示了一种含有该新型2-吡啶酮衍生物的药物组合物。在通式（1）中，R1代表C1-6烷基或C1-6烷氧基；R2代表C1-6烷基或C3-8环烷基；R3代表C1-6烷基、C6-10芳基-C1-6烷基、C1-6烷氧基-C1-6烷基或由通式（2）表示的基团（其中A代表氮原子或CH，R5代表氢原子或C1-6烷氧基）；R4代表由通式（3）或（4）表示的基团。

  公开号：

  US20120225896A1

文献信息

• TRICYCLIC GYRASE INHIBITORS
  申请人：Bensen Daniel

  公开号：US20120238751A1

  公开（公告）日：2012-09-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有式I结构的化合物，以及作为抗菌有效的三环酶抑制剂的药用盐、酯和前药，相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
• HETEROCYCLIC AMINE DERIVATIVES
  申请人：Galley Guido

  公开号：US20120245172A1

  公开（公告）日：2012-09-27

  The present invention relates to compounds of formula I wherein A, B, X, Y, Ar, R 1 , R 2 , R′, m and n are as defined herein and to pharmaceutical active acid addition salts thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中A、B、X、Y、Ar、R1、R2、R′、m和n的定义如本文所述，并且涉及其药用活性酸盐。式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意力缺陷多动障碍（ADHD）、与压力相关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、以及代谢障碍如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍、以及心血管疾病。
• [EN] HETEROCYCLIC AMINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINES HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012126922A1

  公开（公告）日：2012-09-27

  The present invention relates to compounds of formula (I) wherein R1 is hydrogen, lower alkyl, halogen, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, nitro, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, -O-CH2-C3-6-cycloalkyl, -O-(CH2)2-O-lower alkyl, S(O)2CH3, SF5, -C(O)NH-lower alkyl, phenyl, -O-pyrimidinyl, optionally substituted by lower alkoxy substituted by halogen, or is benzyl, oxetanyl or furanyl; m Ar is aryl or heteroaryl, selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo[d][1.3]dioxolyl, 5,6,7,8- tetrahydro-quinazolinyl, pyrazolyl, pyrazinyl, pyridazinyl, or 1,3,4-oxadiazolyl; Y is a bond, -CH2-, -CH2CH2-, -CH(CF3)- or -CH(CH3)-; R2 is hydrogen or lower alkyl; A is CR or N; and R is hydrogen, cyano, halogen or lower alkyl; R' is hydrogen or halogen; with the proviso that when R' is halogen, then A is CH; B is CH or N; n is 0, 1 or 2; X is a bond, -CH2- or -O-; pharmaceutical active acid addition salts thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及以下式（I）的化合物，其中R1是氢、低碳基、卤素、被卤素取代的低碳基、低烷氧基、被卤素取代的低烷氧基、氰基、硝基、C3-6环烷基、-CH2-C3-6环烷基、-O-CH2-C3-6环烷基、-O-(CH2)2-O-低碳基、S(O)2CH3、SF5、-C(O)NH-低碳基、苯基、-O-嘧啶基，或是被低烷氧基取代的被卤素取代的苯基、或者是苄基、氧杂环戊二烯基或呋喃基；m Ar是芳基或杂芳基，选自苯基、萘基、嘧啶基、吡啶基、苯并噻唑基、喹啉基、喹唑啉基、苯并[d][1.3]二噁基、5,6,7,8-四氢喹唑啉基、吡唑基、吡嗪基、吡啶啉基或1,3,4-噁二唑基；Y是键、-CH2-、-CH2CH2-、-CH(CF3)-或-CH(CH3)-；R2是氢或低碳基；A是CR或N；R是氢、氰基、卤素或低碳基；R'是氢或卤素；但是如果R'是卤素，则A是CH；B是CH或N；n是0、1或2；X是键、-CH2-或-O-；以及它们的药用活性酸盐。现已发现，式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、躁郁症、注意力缺陷多动障碍（ADHD）、与压力有关的障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用以及代谢障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、脂质代谢异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME
  申请人：Miura Toru

  公开号：US20120122906A1

  公开（公告）日：2012-05-17

  Disclosed is a novel compound which has both angiotensin II receptor antagonist activity and PPARγ activating activity, and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, kidney diseases, arteriosclerosis, inflammatory diseases, type 2 diabetes, diabetic complication, insulin resistant syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. Also disclosed is a pharmaceutical composition which contains the novel compound. Specifically disclosed are: a sulfonamide derivative represented by general formula (I), a salt thereof, or a solvate of the derivative or salt; and a pharmaceutical composition which contains the sulfonamide derivative, a salt thereof, or a solvate of the derivative or salt. (In the formula, R 1 represents a C 1-6 alkyl group; R 2 and R 3 each represents a C 1-6 alkyl group or the like; and R 4 represents a hydrogen atom, a C 1-6 alkyl group, a C 1-6 alkanoyl group or a C 3-8 cycloalkylcarbonyl group.)

  本发明揭示了一种新型化合物，具有血管紧张素II受体拮抗活性和PPARγ激活活性，可用作高血压、心脏疾病、心绞痛、脑血管疾病、脑循环障碍、缺血性外周循环障碍、肾脏疾病、动脉硬化、炎症性疾病、2型糖尿病、糖尿病并发症、胰岛素抵抗综合征、X综合征、代谢综合征和高胰岛素血症的预防和/或治疗剂。还揭示了一种含有该新型化合物的药物组合物。具体揭示了：一种由通式（I）表示的磺胺衍生物，其盐或该衍生物或盐的溶剂；以及含有该磺胺衍生物、其盐或该衍生物或盐的溶剂的药物组合物。（在该式中，R1代表C1-6烷基基团；R2和R3各代表C1-6烷基基团或类似物；R4代表氢原子、C1-6烷基基团、C1-6烷酰基团或C3-8环烷基羰基团。）
• NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME
  申请人：Miura Toru

  公开号：US20120165353A1

  公开（公告）日：2012-06-28

  Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R 5 or a nitrogen atom; R 1 represents a C 1-6 alkyl group; R 2 represents a C 1-6 alkyl group or a C 3-8 cycloalkyl group; and R 3 , R 4 , R 5 independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group, a halo-C 1-6 alkyl group, or a C 1-6 alkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.

  本发明公开了一种新型化合物，其既具有对血管紧张素II受体的拮抗活性，又具有PPARγ激活活性，因此可用作预防和/或治疗高血压、心脏疾病、动脉硬化、2型糖尿病、糖尿病并发症、代谢综合征等药物；以及含有该化合物的制药组合物。具体公开了：由通式（I）表示的化合物（其中环A表示吡啶环；环B表示四唑环或氧代噻唑-5（4H）-酮环；X表示C—R5或氮原子；R1表示C1-6烷基；R2表示C1-6烷基或C3-8环烷基；R3、R4、R5独立地表示氢原子、卤素原子、C1-6烷基、卤代C1-6烷基或可能具有取代基的C1-6烷氧基），该化合物的盐或该化合物或盐的溶剂合物；以及含有该化合物、盐或溶剂合物的制药组合物。